The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy
Open accessAbstract
Aims: Glucagon-like peptide-1 receptor agonists are effective treatments for type 2 diabetes, effectively lowering glucose without weight gain and with low risk for hypoglycemia. However, their influence on the retinal neurovascular unit remains unclear. In this study, we analyzed the effects of the GLP-1 RA lixisenatide on diabetic retinopathy. Methods: Vasculo- and neuroprotective effects were assessed in experimental diabetic retinopathy and high glucose-cultivated C. elegans, respectively. In STZ-diabetic Wistar rats, acellular capillaries and pericytes (quantitative retinal morphometry), neuroretinal function (mfERG), macroglia (GFAP western blot) and microglia (immunohistochemistry) quantification, methylglyoxal (LC–MS/MS) and retinal gene expressions (RNA-sequencing) were determined. The antioxidant properties of lixisenatide were tested in C. elegans. Results: Lixisenatide had no effect on glucose metabolism. Lixisenatide preserved the retinal vasculature and neuroretinal function. The macro- and microglial activation was mitigated. Lixisenatide normalized some gene expression changes in diabetic animals to control levels. Ets2 was identified as a regulator of inflammatory genes. In C. elegans, lixisenatide showed the antioxidative property. Conclusions: Our data suggest that lixisenatide has a protective effect on the diabetic retina, most likely due to a combination of neuroprotective, anti-inflammatory and antioxidative effects of lixisenatide on the neurovascular unit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







![Fig. 8 Formation of reactive oxygen species (ROS) in C. elegans. Nematodes were cultured under standard (S) or high glucose (HG) conditions. For additional treatment, lixisenatide was added at concentration of 6 µM, 2 µM, 0.6 µM, 0.2 µM and 0.02 µM to the high glucose condition (HG + Lixi). ROS formation was detected by confocal laser scanning microscopy (CLSM) of ethidium-labeled nematodes at 12 days of age and quantified by calculation of mean pixel values [arbitrary units (AU)/pixel]. Shown are the results of one representative experiment from three independent experiments. a Representative CLMS images of the respective groups. b Summary of quantified ROS formation. Shown are MW ± SD (n = 7–21). Significance against HG condition was calculated using Tukey's multiple comparisons test, ***p < 0.001](https://figures.cochat.ai/paper-figures/de16c498921f4c45982e556f75ed59b7/the-effect-of-glp-1-receptor-agonist-lixisenatide-on-experimental-diabetic-figure-8.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This was achieved by decreasing the expression of proinflammatory cytokines such as tumor necrosis factor (TNF), interleukin-6 (IL-6), and interleukin-8 (IL-8).15,351,352”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [351]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581 · cited 1×
“This work-flow included alignment to a reference rat gene model, quantification, normalization, and finally detection of differentially expressed genes using the DESeq2 module (EMBL) [23].”
MethodGene Expression Omnibus: NCBI gene expression and hybridization array data repository
Edgar, R. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.1.207 · Cited by 13,288
The Pathobiology of Diabetic Complications
Brownlee, M. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1615 · Cited by 5,339 · cited 4×
“This, in turn can induce vasoregression, neuronal dysfunction and inflammation [28].”
BackgroundInfluentialNormalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277 · cited 1×
“The DDP4 inhibitor in this study had the potential to reduce vascular protection by inhibiting GLP-1 degradation products such as GLP-1(9–37) and GLP-1(9–36) amide, as the degradation products of active GLP-1 are supposed inhibitors of mitochondrial ROS overproduction [34, 35].”
BackgroundSelf-citationKimura, K. D., Tissenbaum, H. A., Liu, Y., & Ruvkun, G. (1997) · Science · doi:10.1126/science.277.5328.942 · Cited by 2,245 · cited 1×
“elegans as a model organism very attractive [25, 26].”
BackgroundHammes, H.-P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., et al. (2003) · Nature Medicine · doi:10.1038/nm834 · Cited by 785 · cited 1×
“Previous studies have shown that thiamine and benfotiamine (a lipophilic form of thiamine) prevent retinal pericytes from apoptosis induced by mitochondrial dysfunction, as well as retinal histopathology and other metabolic pathways associated with the development of diabetic retinopathy[47, 48].”
BackgroundSelf-citationYuan, T., Yang, T., Chen, H., Fu, D., Hu, Y., Wang, J., Yuan, Q., Yu, H., Xu, W., & Xie, X. (2019) · Redox Biology · doi:10.1016/j.redox.2018.09.025 · Cited by 743 · cited 1×
“, strokes, myocardial infarctions) and microvascular complications such as neuropathy, nephropathy and retinopathy [1].”
BackgroundAnatomical Profiling of G Protein-Coupled Receptor Expression
Regard, J. B., Sato, I. T., & Coughlin, S. R. (2008) · Cell · doi:10.1016/j.cell.2008.08.040 · Cited by 693 · cited 1×
“…some published evidence for a functional receptor in the mouse [36, 37], data have been published that using specific molecular tools only few ganglion cells in the healthy human retina express the receptor, while in advanced diabetic retinopathy, the receptor is no longer detectable [29, 38, 39].”
BackgroundGlucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543 · cited 1×
“This leads to improved blood sugar control in type 2 diabetes [12–15].”
Background
Research works printed but not linked: 2
- Abràmoff MD, Magalhães PJ, Ram SJ (2004) Image processing with ImageJ. Biophotonics Int 11(7):36–42
- Da Silva S et al (2010) Antioxidants in the prevention and treatment of diabetic retinopathy a review. J Diabet Metabol 1:111. https://doi.org/10.4172/2155-6156.100011 · doi:10.4172/2155-6156.100011
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
GLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 62
Shi, T.-F., Zhou, Z., Jiang, W., Huang, T.-L., Yu, M., Yu, M., Si, J., & Li, L. (2024) · Redox Report · doi:10.1080/13510002.2024.2382943 · Cited by 53
“Lixisenatide controls the inflammatory response caused by oxidative stress by regulating the Est2 [61].”
BackgroundBuckley, A. J., Tan, G. D., Gruszka-Goh, M. H., Scanlon, P. H., Ansari, I., & Suliman, S. G. I. (2025) · Diabetologia · doi:10.1007/s00125-025-06466-8 · Cited by 38
An update on ocular effects of antidiabetic medications
Sadeghi, E., Rahmanipour, E., Valsecchi, N., Kapoor, S., Cicinelli, M. V., & Chhablani, J. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.01.010 · Cited by 23
Metadata
- Authors
- Oezer, K., Kolibabka, M., Gassenhuber, J., Dietrich, N., Fleming, T., Schlotterer, A., Morcos, M., Wohlfart, P., & Hammes, H.-P.
- Affiliations
- Heidelberg University (DE)
- Sanofi (Germany) (DE)
- Corresponding author
- Oezer, Kuebra
- ORCID
- Venue
- Acta Diabetologica
- Published
- 2023-07-09
- Volume
- 60
- Issue
- 11
- Pages
- 1551-1565
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- PMC
- PMC10520173
- OpenAlex
- W4383676238
- Cited by
- 22
- References
- 56
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 6
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Diabetologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- GRK 1874/2 DIAMICOM
- SFB 1118
- Sanofi-Aventis Deutschland
- European Foundation for the Study of Diabetes
- NIH Office of Research Infrastructure Programs
- Medizinische Fakultät Mannheim der Universität Heidelberg
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- lixisenatide, GLP-1 receptor agonists, diabetic retinopathy, neurovascular unit, retinal neuroprotection, retinal vasculature, pericytes, microglial activation, macroglia, ETS2, inflammation, oxidative stress, antioxidant activity, methylglyoxal, retinal gene expression, streptozotocin-induced diabetes, Caenorhabditis elegans
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Antioxidants, Chromatography, Liquid, Diabetes Mellitus, Experimental, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Glucose, Hypoglycemic Agents, Peptides, Caenorhabditis elegans, Rats, Wistar, Rats, Tandem Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy. https://app.cochat.ai/papers/10.1007/s00592-023-02135-7
- The paper
- Oezer, K., Kolibabka, M., Gassenhuber, J., Dietrich, N., Fleming, T., Schlotterer, A., Morcos, M., Wohlfart, P., & Hammes, H.-P. (2023). The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy. Acta Diabetologica. https://doi.org/10.1007/s00592-023-02135-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.